BioCentury

8:00 AM GMT, Feb 10, 2003
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Sifting the Iressa outcomes in Japan

Rates of interstitial lung disease in Japanese patients treated with AstraZeneca plc's Iressa are higher than in Iressa patients in other parts of the world. Last week, a group of experts assembled by the pharma company said it had found no direct relationship between Iressa and ILD. Instead, the difference appears to lie in the way the

Read the full 574 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.